- Home
- AGEN vs AREC Comparison
AGEN vs AREC Comparison
Compare AGEN & AREC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- AREC
- Stock Information
- Founded
- AGEN 1994
- AREC 2013
- Country
- AGEN United States
- AREC United States
- Employees
- AGEN N/A
- AREC N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- AREC Coal Mining
- Sector
- AGEN Health Care
- AREC Energy
- Exchange
- AGEN Nasdaq
- AREC Nasdaq
- Market Cap
- AGEN 38.1M
- AREC 37.9M
- IPO Year
- AGEN 2000
- AREC 2019
- Fundamental
- Price
- AGEN $3.16
- AREC $1.08
- Analyst Decision
- AGEN Buy
- AREC Strong Buy
- Analyst Count
- AGEN 4
- AREC 3
- Target Price
- AGEN $8.00
- AREC $4.33
- AVG Volume (30 Days)
- AGEN 655.0K
- AREC 14.2M
- Earning Date
- AGEN 05-06-2025
- AREC 05-20-2025
- Dividend Yield
- AGEN N/A
- AREC N/A
- EPS Growth
- AGEN N/A
- AREC N/A
- EPS
- AGEN N/A
- AREC N/A
- Revenue
- AGEN $103,463,000.00
- AREC $399,962.00
- Revenue This Year
- AGEN $4.03
- AREC N/A
- Revenue Next Year
- AGEN $5.57
- AREC $3,208.62
- P/E Ratio
- AGEN N/A
- AREC N/A
- Revenue Growth
- AGEN N/A
- AREC N/A
- 52 Week Low
- AGEN $1.38
- AREC $0.38
- 52 Week High
- AGEN $19.69
- AREC $1.68
- Technical
- Relative Strength Index (RSI)
- AGEN 78.44
- AREC 63.66
- Support Level
- AGEN $1.60
- AREC $0.38
- Resistance Level
- AGEN $1.83
- AREC $1.68
- Average True Range (ATR)
- AGEN 0.31
- AREC 0.20
- MACD
- AGEN 0.21
- AREC 0.08
- Stochastic Oscillator
- AGEN 97.52
- AREC 47.71
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About AREC American Resources Corporation
American Resources Corp is a next-generation, environmentally, and socially responsible supplier of high-quality raw materials to the new infrastructure market. The firm is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. The firm has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. Its business model provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure and electrification markets.